Literature DB >> 8400801

Investigations of antisense oligonucleotides targeted against bcl-2 RNAs.

S Kitada1, T Miyashita, S Tanaka, J C Reed.   

Abstract

Expression of the bcl-2 gene becomes deregulated in many non-Hodgkin lymphomas as the result of t(14;18) chromosomal translocations. Because bcl-2 regulates the survival of cells, and because its over-expression is associated with cellular resistance to killing by chemotherapeutic drugs and gamma-irradiation, this gene and its mRNA and protein products represent ideal targets for designing novel therapeutic strategies for the treatment of cancer. Here we describe the effects of an 18-mer phosphodiester oligonucleotide that is complementary to the first 6 codons of the bcl-2 mRNA's open reading frame. When tested for inhibition of in vitro protein synthesis using RNAse-H-supplemented reticulocyte lysates and RNA prepared by in vitro transcription of a human bcl-2 cDNA, the bcl-2 antisense (AS) oligomer completely abolished Bcl-2 protein production at 10 microM, but had no effect on the in vitro translation of a chicken bcl-2 RNA that contained three mismatches relative to the oligomer binding site on the human bcl-2 RNA. A control 18-mer having the same base composition as the AS oligomer but with scrambled order (SC) was not inhibitory. Addition of AS and SC oligomers to cultures of a NIH-3T3 fibroblast cell line that had been stably infected with a recombinant retrovirus containing the same human bcl-2 cDNA used for in vitro transcription/translation experiments revealed concentration-dependent reductions in the relative levels of the 26-kD human Bcl-2 protein (as determined by immunoblotting) by the AS but not by the SC oligomer. Similar results were obtained when AS and SC oligomers were applied to a t(14;18)-containing lymphoma cell line SU-DHL-4 that was cultured in low-serum media. When used at 200 microM, the bcl-2 AS oligomer produced 84-95% reductions in Bcl-2 protein levels in SU-DHL-4 cells but had relatively little effect on the levels of other mitochondrial control proteins, suggesting that the inhibitory effects were specific. Treatment of SU-DHL-4 cells with AS oligomer lead to essentially complete loss of bcl-2 mRNA from cells within 1 day of addition to cultures, but presumably because of the long half-life of the Bcl-2 protein (approximately 14 h), commensurate reductions in Bcl-2 protein levels did not occur until 3 days.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400801     DOI: 10.1089/ard.1993.3.157

Source DB:  PubMed          Journal:  Antisense Res Dev        ISSN: 1050-5261


  15 in total

1.  Programmed cell death (apoptosis) in cord blood lymphocytes.

Authors:  S Aggarwal; A Gupta; S Nagata; S Gupta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

2.  Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

Authors:  J A Toretsky; Y Connell; L Neckers; N K Bhat
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis.

Authors:  C Koumenis; A Giaccia
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

4.  A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.

Authors:  Glenn Liu; Jill Kolesar; Douglas G McNeel; Catherine Leith; Kathy Schell; Jens Eickhoff; Fred Lee; Anne Traynor; Rebecca Marnocha; Dona Alberti; James Zwiebel; George Wilding
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

5.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes.

Authors:  S Krajewski; S Bodrug; R Gascoyne; K Berean; M Krajewska; J C Reed
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

6.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

Review 7.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

Review 8.  Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?

Authors:  K Brinkmann; H Kashkar
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

9.  Raman spectroscopic study of radioresistant oral cancer sublines established by fractionated ionizing radiation.

Authors:  Mohd Yasser; Rubina Shaikh; Murali Krishna Chilakapati; Tanuja Teni
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

10.  The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2.

Authors:  T Yang; K M Kozopas; R W Craig
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.